Neoadjuvant pembrolizumab and chemotherapy in resectable clinical stage III non-small-cell lung cancer: a retrospective cohort study

BACKGROUND: Pembrolizumab has been shown to be effective and safe in improving the survival of patients with advanced non-small-cell lung cancer (NSCLC). However, the effectiveness and safty of pembrolizumab in the induction treatment of patients with potential resectable clinical stage III NSCLC re...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Guangyin, Zhang, Hongyu, Xu, Fengkai, Lu, Chunlai, Zhu, Qiaoliang, Grossi, Francesco, Divisi, Duilio, Ma, Teng, Gu, Jie, Ge, Di
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9903088/
https://www.ncbi.nlm.nih.gov/pubmed/36762056
http://dx.doi.org/10.21037/tlcr-22-871

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9903088/
https://www.ncbi.nlm.nih.gov/pubmed/36762056
http://dx.doi.org/10.21037/tlcr-22-871

Ejemplares similares